The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense:
Agentase LLC, Pittsburgh, Pa., has been awarded an $11,206,720 cost contract. The work will support the Defense Advanced Research Project Agency (DARPA) In Vivo Nanoplatforms (IVN) program.
IVN seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease.
Work will be performed in Pittsburgh, Pa., (44.59 percent); Cambridge, Mass., (8.04 percent); Davis, Calif., (40.92 percent) and College Station, Texas, (6.45 percent). The estimated completion date is April 14, 2015. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is DARPA, Arlington, Va., (HR0011-14-C-0030).
In 2012, DARPA released tangent Broad Agency Announcements to support development of In vivo Nanoplatforms for Therapeutics (IVN:Tx) and In vivo Nanoplatforms for Diagnostics (IVN:Dx).
Source: Defense.gov, FBO.gov
